Alon Ben-Noon, CEO of NeuroSense Therapeutics
NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS
The study, containing 15 patients, is scheduled to continue for an additional 6 months.
Medical Device News Magazine reports breaking biotechnology news in addition to medical device news.
- Go to the previous page
- 1
- …
- 314
- 315
- 316
- 317
- 318
- 319
- 320
- …
- 323
- Go to the next page